Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (moderate certainty).
1 finding from 1 review
Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
Major bleeding · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in major haemorrhage compared with standard care (low certainty).
1 finding from 1 review
Minor haemorrhage · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in minor haemorrhage compared with standard care (moderate certainty).
1 finding from 1 review
Thromboembolic events · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower thromboembolic events compared with standard care (moderate certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants experiencing at least 1 exacerbation… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Mortality Deaths · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in mortality Deaths compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Complications · Patients with 3 to 6 mm of residual bone height at the sinus floor
One-stage crestal-approach sinus lift with autogenous bone and 8 mm… showed no clear difference in complications compared with lateral-window sinus lift with 50% autogenous bone/50% Bio-Oss and…; GRADE not reported.
1 finding from 1 review
Implant failure · Patients with 3 to 6 mm of residual bone height at the sinus floor
One-stage crestal-approach sinus lift with autogenous bone and 8 mm… showed no clear difference in implant failure compared with lateral-window sinus lift with 50% autogenous bone/50% Bio-Oss and…; GRADE not reported.
1 finding from 1 review
Partial graft loss · Patients with 3 to 6 mm of residual bone height at the sinus floor
One-stage crestal-approach sinus lift with autogenous bone and 8 mm… showed no clear difference in partial graft loss compared with lateral-window sinus lift with 50% autogenous bone/50% Bio-Oss and…; GRADE not reported.
1 finding from 1 review
Prosthesis failure · Patients with 3 to 6 mm of residual bone height at the sinus floor
One-stage crestal-approach sinus lift with autogenous bone and 8 mm… showed no clear difference in prosthesis failure compared with lateral-window sinus lift with 50% autogenous bone/50% Bio-Oss and…; GRADE not reported.
1 finding from 1 review
Intervention not reported
Exercise capacity (5‐ or 6‐minute walking distance on cylinder air) · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
1 finding from 1 review
Intervention not reported
Mortality · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life (dyspnoea) Measured on the CRQ, the output is a number from 0 to 7, where higher on the scale is better. MID is 0.5. · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention probably leads to higher quality of life (dyspnoea) Measured on the CRQ, the output is a… (moderate certainty).
1 finding from 1 review